1. Allogene's Off-the-Shelf CAR-T Therapy Nears Critical Early Study Readout
Allogene Therapeutics is approaching a pivotal moment for its 'off-the-shelf' CAR-T therapy, with an early but critical study readout on the horizon. This data point represents a significant test for the company's core technology platform, which aims to revolutionize cancer treatment by moving away from personalized, p...